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Defects in interleukin-1β (IL-1β)–mediated cellular responses con-
tribute to Alzheimer’s disease (AD). To decipher the mechanism
associated with its pathogenesis, we investigated the molecular
events associated with the termination of IL-1β inflammatory re-
sponses by focusing on the role played by the target of Myb1
(TOM1), a negative regulator of the interleukin-1β receptor-1 (IL-
1R1). We first show that TOM1 steady-state levels are reduced in
human AD hippocampi and in the brain of an AD mouse model
versus respective controls. Experimentally reducing TOM1 affected
microglia activity, substantially increased amyloid-beta levels, and
impaired cognition, whereas enhancing its levels was therapeutic.
These data show that reparation of the TOM1-signaling pathway
represents a therapeutic target for brain inflammatory disorders
such as AD. A better understanding of the age-related changes in
the immune system will allow us to craft therapies to limit detri-
mental aspects of inflammation, with the broader purpose of
sharply reducing the number of people afflicted by AD.
target of Myb1 | TOM1 | IL-1R1 | Alzheimer’s disease | 3xTg-AD
Immune responses need to be tightly regulated in terms of in-tensity, class, and duration to prevent molecular and cellular
damage. While in young healthy individuals inflammation is self-
limited, disturbances in the immune system of older subjects may
result in a state of low-grade chronic inflammation (1, 2). In the
brain, such processes have been implicated with a variable de-
gree of importance in almost all age-related neurodegenera-
tive disorders including Alzheimer’s disease (AD) (3, 4). The
endosomal system, known principally for its role in the uptake of
molecules from the plasma membrane and surrounding envi-
ronment, is increasingly being recognized as a critical component
in the regulation of inflammatory responses (5, 6). For example,
trafficking and sorting of proinflammatory receptors, for which
the final destination is the degradation in lysosomes, are known
to play an important role in the down-regulation of signaling
following ligand stimulation (7–9).
Among numerous inflammatory pathways, the interleukin-1β
(IL-1β)–signaling pathway plays a critical pathogenic role in AD
(10–12). IL-1β is up-regulated in the brain, cerebrospinal fluid,
and plasma of AD patients, directly affecting pathology devel-
opment (13–15). Previous data indicate that the initial increase
in IL-1β levels is associated with the buildup of intracellular Aβ
and occurs prior to any apparent glia activation in young 3xTg-
AD mice, suggesting an association between both events in neurons
(10, 16). A major site of expression of IL-1β and its receptor,
interleukin-1 receptor-1 (IL1-R1), is the hippocampus, implicating
their potential role in modulating hippocampal memory function.
Elevated levels of this cytokine in the brain have deleterious effects
on consolidation of spatial memory and in hippocampus-dependent
contextual tasks (11, 17). IL-1β impairs long-term potentiation
(LTP) in synaptosomes and, due to a reconfiguration in the IL-1
receptor subunit AcP, aged hippocampal synapses become more
sensitive to this cytokine (18). Additional proposed mechanisms for
the impairment evoked by IL-1β in the aging brain may involve the
activation of mitogen-activated protein kinases (19–21) and brain-
derived neurotrophic factor (BDNF), since the consolidation of
hippocampus-dependent memory, and associated forms of synaptic
plasticity, are dependent upon this molecule (22).
Once bound by IL-1β, IL-1R1 binds to target of Myb1 (TOM1)
and is internalized to endosomes to ensure proper resolution
of the inflammatory response (23–26). TOM1 is predomi-
nantly present in the cytosol and interacts with proteins such
as clathrin and toll-interacting protein (Tollip) to regulate
endosomal trafficking and lysosomal degradation of ubiquitinated
proteins (23, 27). Given that defects in intracellular protein
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As we age, the innate immune system becomes dysregulated
and is characterized by persistent inflammatory responses, and
the chronic inflammation mediated by inflammatory receptors
represents a key mechanism by which amyloid-beta (Aβ) drives
the development of cognitive decline in Alzheimer’s disease
(AD). A crucial aspect of this process is a failure to resolve in-
flammation, which involves the suppression of inflammatory
cell influx and the endocytosis of inflammatory receptors. We
found that ablation of the endosomal adaptor target of Myb1
(TOM1) worsens neuroinflammation, impairs microglial phago-
cytosis, and significantly exacerbates amyloid deposition. Con-
versely, restoration of TOM1 reverses these effects and reduces
Aβ pathology. These results highlight the importance of endosomal
adaptors and their interaction with inflammatory receptors in
the pathogenesis of AD.
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clearance (e.g., autophagy and ubiquitin-proteasome system) and
trafficking (e.g., endocytosis) have been implicated in the regula-
tion of IL-1β signaling (24, 28) and AD (29–31), it is plausible that
the disruption of these processes may result in overexpression of
proinflammatory receptors leading to exacerbated immune re-
sponses and cognitive decline.
Fig. 1. Reduced TOM1 levels are found in AD brains and in neuronal cell culture in the presence of ADDLs. RepresentativeWestern blots and quantification show
increased IL-1R1 and reduced TOM1 levels in the hippocampus of AD patients (A). Immunohistochemistry staining for TOM1 in AD and age-matched controls
(Scale bars, 250 μm.) (B). Representative Western blots (C, G, and K) and quantification show increased IL-1R1 (D), decreased TOM1 (E), and unchanged Tollip (F)
levels in primary mouse neuronal cell culture after incubation with ADDLs. No significant changes were observed in the levels of IL-1R1, TOM1, or Tollip in as-
trocytes (G–J) or iPSC-derived human microglia (K–N) in response to ADDLs. Data are represented as mean ± SEM. ANOVA, *P ≤ 0.05, n = 3–8 per group.
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It remains an open question whether TOM1 plays a role in IL-
1R1 signaling in the pathogenesis of AD. Our findings provide
in vivo and in vitro evidence that reduced TOM1 impairs IL-1R1
neuronal internalization and promotes amyloid plaque deposition.
Ablating TOM1 also enhances the overall proinflammatory milieu
and promotes detrimental changes in microglial morphology and
function. This work identifies a critical role for TOM1 in AD,
suggesting that impairments on this pathway could dramatically
affect the development and progression of AD.
Results
Impairment in TOM1 Levels Causes IL-1R1 Overexpression in AD. For
efficient degradation, the IL-1R1 needs to bind to Tollip and
TOM1 in order to be internalized to endosomes (23–25). We
found that, while the steady-state levels of Tollip are not altered,
the expression of TOM1 is significantly reduced in human AD
brains and associated with a corresponding increase in the levels
of IL-1R1 (Fig. 1 A and B). To investigate the potential effects of
amyloid-beta (Aβ) in this signaling pathway, we treated primary
mouse astrocytic and hippocampal neuronal cultures and in-
duced pluripotent stem cell (iPSC)-derived human microglia
with Aβ-derived diffusible ligands 1–42 (ADDLs). We observed
that, compared to control, the neuronal level of IL-1R1 was
increased with growing concentration and incubation time of
ADDLs while Tollip levels were not changed (Fig. 1 C–F).
Conversely, no significant changes were observed in astrocytes or
iPSC-microglia (Fig. 1 G–N). In AD transgenic mouse brains,
TOM1 reduction was also accompanied by increased IL-1R1 and
IL-1β levels (Fig. 2 A–C and SI Appendix, Fig. S2A). To further
investigate this matter, we injected adeno-associated virus (AAV)
constructs designed to overexpress (AAV1-CAG-mTOM1–WPRE)
or knock down (AAV1-GFP-U6-mTOM1-shRNA) TOM1 in the
hippocampus of 9-mo-old 3xTg-AD mice. There was a higher in-
fection of neuronal cells, followed by reduced microglial and no
astrocytic viral infection (SI Appendix, Fig. S1). By knocking down
TOM1, the levels of both IL-1R1 and IL-1β were increased (Fig. 2
A–C and SI Appendix, Fig. S2A). No changes in other inflammatory
receptors—TLR4 and TNFR—were observed, suggesting that
TOM1 works specifically with IL-1R1 in AD (SI Appendix, Fig.
S2B). We have also confirmed the expression of IL-1R1 in hippo-
campal neuronal and microglial cells, with lower expression de-
tected in astrocytes (SI Appendix, Fig. S2C) (32, 33). In the
hippocampus of 3xTg-ADmice, the receptor was found in both pre-
and postsynaptic terminals, with a higher signal observed in the
postsynapse (Fig. 2 D1 and D2). In TOM1-WPRE animals, how-
ever, the signal not only was more prominent inside the den-
drites, but also was associated with the endoplasmic reticulum, in
sharp contrast to the high IL-1R1 signal associated with the mem-
brane in Null-AAV– and TOM1-shRNA–treated mice (Fig. 2D).
These results indicate that the dysfunction in TOM1-mediated
endocytosis and degradation exacerbates the steady-state levels
of IL-1R1 in AD.
Knockdown of TOM1 Exacerbates Immune Response. Considering
the importance of TOM1 in shuttling internalized IL-1R1 to
lysosomes for degradation, it is possible that reduced TOM1
levels lead to a state of overactivation of the immune response in
the brain. In addition to increased IL-1β levels, TOM1-shRNA
increased 2 other proinflammatory cytokines, tumor necrosis
factor-α (TNF-α) and KC-GRO, whereas the overexpression of
TOM1 increased interleukin-2, a cytokine involved in the control
of inflammation and reduction of AD hallmarks in the APP/
PS1ΔE9 model (SI Appendix, Fig. S3 A–D) (34). We used the
NanoString nCounter mouse inflammation gene expression
panel to perform expression profiling of RNAs that are altered
by the manipulation of TOM1 in 3xTg-AD mouse hippocampus.
Of the 253 mRNAs tested, 93 transcripts were significantly
changed among different groups (SI Appendix, Table S2),
including genes related to AD onset, chemokines, cytokines, and
complement system components. Thus, alterations of genes in
specific inflammation-related pathways represent networks al-
tered in response to TOM1 modification.
Reduced TOM1 Impairs Microglial Phagocytic Efficiency. The TOM1-
shRNA–treated mice presented changes in the glial cell mor-
phology, with a reduction in the total length of processes, the
number of branches per microglia cell, and microglial loading
(Fig. 3 A–D), but no significant changes in the number of Iba-1–
positive cells in the hippocampus of any of the groups analyzed
(Fig. 3E). A similar pattern was also seen for astrocytes (Fig. 3
F–J). Among other important roles, microglia are the brain’s
primary cellular agent for clearing extracellular Aβ, so we quan-
tified the proportion of Aβ inside microglial phagolysosomes.
TOM1-WPRE mice had reduced plaque deposition and in-
creased immunofluorescence intensity and localization of glia
within the center of plaques, suggesting that TOM1 deficiency
alters the phagocytic activity and the glial response to Aβ plaques
(Fig. 4 A, A1 and A2). We further analyzed this response by
infecting iPSC-derived human microglia cultures with Lenti open
reading frame (ORF) particles, TOM1 (Myc-DDK–tagged), in
Fig. 2. Reduced TOM1 is accompanied by increased IL-1R1 and IL-1β levels.
Representative Western blots and quantification show increased IL-1R1 in
Null and TOM1-shRNA 3xTg-AD mice (A). TOM1 is reduced in Null 3xTg-AD
mice, whereas the animals treated with TOM1-WPRE show significantly in-
creased levels of this protein (B). IL-1β levels are increased in the hippo-
campus of 3xTg-AD mice treated with Null and TOM1-shRNA AAVs vs.
TOM1-WPRE mice (C). Images obtained through electron microscopy re-
veal the IL-1R1 presence in pre (pink) and postsynaptic (blue) terminals (D).
In Null (D1 and D4) or TOM1-shRNA–treated mice (D3 and D6), the receptor
is expressed closer to the membrane, whereas it appears more internalized
and associated with the endoplasmic reticulum on TOM1-WPRE mice (D2
and D5). Black arrows: receptor expression; orange arrows: synapses. (Scale
bars: D1, D2, and D4, 0.5 μm; D3, 200 nm; D5 and D6, 0.2 μm.) Data are
represented as mean ± SEM. ANOVA, *P ≤ 0.05; n = 3–4 per group.
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order to increase TOM1 levels, followed by incubation with
fluorescent ADDLs or Aβ fibrils. We then measured the rate of
Aβ phagocytosis in a real-time live-imaging system over 24 h.
Quantification of bright red fluorescence, indicating cellular
uptake of Aβ, revealed significantly increased phagocytosis in
TOM1-overexpressing cells (Fig. 4 B–D). Compared to the soluble
oligomers, Aβ fibrils were phagocytosed at a much faster rate in
the presence of increased TOM1.
Aβ Deposition Is Enhanced by the Reduction in TOM1. We next
addressed whether the manipulation of TOM1 and microglial
phagocytosis would impact Aβ pathology in vivo. The TOM1-
shRNA mice presented a greater number and area of Aβ plaques
(Fig. 4 E and F and SI Appendix, Fig. S4A), as well as increased
levels of soluble Aβ38, Aβ40, and Aβ42 and of insoluble Aβ40 and
Aβ42 (Fig. 4 G and H). Interestingly, we found irregular staining
and TOM1 accumulation in proximity to amyloid deposits (SI
Appendix, Fig. S4B). As expected, 3xTg-AD mice presented
higher levels of amyloid precursor protein (APP), compared to
the nontransgenic (nTg) mice, and increased TOM1 levels led to
reduction of β-site APP-cleaving enzyme 1 (BACE1), but not of
the other proteins related to the amyloid precursor protein
(APP) processing (Fig. 5 A–E). The colocalization of TOM1 in
dystrophic neurites and neurofibrillary tangles, as well as with
proteins from the ubiquitin-proteasome and the autophagy-
lysosome systems—2 systems that were first thought to be in-
dependent but are actually capable of cross talk—has been
reported (35). p62 is an autophagy substrate used as a reporter
of autophagy activity, and it delivers ubiquitinated proteins,
such as tau, to the proteasome for degradation (36, 37). In-
creased levels of p62 facilitate the removal of Aβ and tau in the
APP/PS1ΔE9 mouse model (38). We found a significant
Fig. 3. Ablating TOM1 alters glial morphology. (A) Representative images of microglia (Iba1+) in the hippocampus of 3xTg-AD mice treated with AAV-Null,
AAV-TOM1-WPRE, or AAV-TOM1-shRNA. (Scale bar, 200 μm; Inset, 25 μm.) Total process length per microglia (B), the number of branches per microglia (C),
and the microglial loading are significantly reduced by TOM1-shRNA (D), while the number of microglia cells does not change (E). Representative images of
astrocytes (GFAP+) in the hippocampus of 3xTg-AD mice treated with AAV-Null, AAV-TOM1-WPRE, and AAV-TOM1-shRNA (F). (Scale bar, 200 μm; Inset,
25 μm.) Total process length per astrocyte (G), the number of branches per astrocyte (H), and the astrocyte loading (I) are significantly reduced by TOM1-
shRNA, while the number of astrocytes (J) does not change. Data are represented as mean ± SEM. ANOVA, *P ≤ 0.05; n = 6 per group.
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increase in p62 levels in TOM1-WPRE mice, but no significant
changes in LC3B-II/LC3B-I ratio (Fig. 5 F and G), supporting
the idea that changes in TOM1 interfere directly with the
microglial ability to remove Aβ. Thus, these protein-degradation
systems could be responsible for the dysfunction of TOM1 in the
presence of Aβ plaques and, consequently, of IL-1R1 in the
AD brain.
Loss of TOM1 Causes the Exacerbation of Cognitive Decline. To de-
termine whether TOM1 deficiency affects AD-related cognitive
changes in mice, we assessed spatial learning and memory using
the Morris water maze. First, we found that changes in TOM1
levels do not impact cognitive function in healthy nTg animals.
However, acquisition performance in 3xTg-AD mice treated with
TOM1-WPRE was similar to that observed in nTg mice, sug-
gesting that these animals learned the location of the hidden
platform more quickly than did AD mice treated with Null-AAV
or TOM1-shRNA mice (Fig. 6A). During the test day, TOM1-
shRNA–treated 3xTg-AD mice spent less time in the zone of the
platform, crossed the platform fewer times, and took longer to
find the hidden platform (Fig. 6 B–D), and these differences
were not due to locomotor impairments as demonstrated by
distance and speed analyses (Fig. 6 E and F). Moreover, these
animals also presented a reduced percentage of freezing be-
havior in the contextual fear-conditioning test (Fig. 6G), but no
changes were seen in the novel object task (Fig. 6H). We have
also measured the levels of BDNF and pCREB/CREB, as these
are important factors related to learning and memory processes
(39–41), but no significant changes were found. Altogether, our
studies indicate that TOM1 rescue the cognitive function in AD
mice indirectly by changing levels of Aβ and proinflammation,
without altering memory-related pathways.
Tollip Ablation Worsens Cognition without Affecting Aβ Levels. The
induced ubiquitination of IL-1R1 by IL-1β is part of the basis for
interaction with Tollip, which is also required for sorting of the
receptor for lysosomal degradation. Supportive of this possibility
is the observation that the production of the proinflammatory
cytokines interleukin-6 and TNF-α was significantly reduced af-
ter stimulation with low doses of IL-1β and lipopolysaccharide in
Fig. 4. TOM1 ablation reduces Aβ phagocytosis. Representative immunohistochemical images of Aβ plaques (6E10: red), microglia (Iba1: blue), and microglial
phagolysosomes (CD68: green) (A, A1, and A2). Three-dimensional reconstruction of Iba1, Aβ, and phagolysosomes inside microglia (A1 and A3). (Scale bars, A
and A1: 150 μm; A2: 100 μm.) Quantification of Aβ within phagolysosomes revealed a significant increase in Aβ internalization in TOM1-WPRE mice (A3). iPSC-
derived microglia cells were infected with TOM1 lentivirus and incubated with ADDLs or Aβ fibrils, and the rate of microglia phagocytosis was measured over
24 h in real time. TOM1 infection significantly increased the phagocytosis of 100 and 500 nM, as well as Aβ fibrils (B and C). Representative images of 555-
labeled ADDL uptake in iPSC-microglia during live imaging sessions (D). TOM1-shRNA significantly increased the total number (E) and area (F) of Aβ plaques in
the hippocampus of 3xTg-AD mice. Aβ V-PLEX immunoassay reveals significant increase in Aβ38, Aβ40, and Aβ42 in soluble (G) and insoluble (H) hippocampal
lysates from TOM1-shRNA–treated mice. Data are represented as mean ± SEM. ANOVA, *P ≤ 0.05; n = 3–4 per group.
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Tollip knockout mice, suggesting that Tollip may regulate the
magnitude of inflammatory cytokine production (24, 28). Ac-
cordingly, a different cohort of animals was injected with AAV1-
GFP-U6-mTollip-shRNA to knock down Tollip and serve as a
means of comparison to the effects promoted by TOM1 ma-
nipulation. We found reduced levels of Tollip and increased IL-
1R1 in 3xTg-AD-Null–treated mice versus nTg mice, aspects that
were exacerbated by the Tollip-shRNA treatment (SI Appendix,
Fig. S5 A and B). However, levels of IL-1β were not changed with
treatment (SI Appendix, Fig. S5C). Similar to TOM1-shRNA–
treated mice, animals treated with Tollip-shRNA presented a
higher expression of the receptor closer to the cell membrane, as
observed through electron microscopy (SI Appendix, Fig. S5D).
Knocking down Tollip also modified the morphology of micro-
glia and astrocytes, without changing the number of these cells
(SI Appendix, Fig. S5 E–N), and increased the area of Aβ plaques
(SI Appendix, Fig. S6A) but did not significantly change any of
the soluble and insoluble Aβ levels measured (SI Appendix, Fig.
S6 B–G). As seen with the other treatment groups, Tollip-
shRNA–treated mice had higher escape latency during the ac-
quisition phase of the Morris water maze and a reduced number
of crosses (SI Appendix, Fig. S6 H–M), and the freezing behavior
in the contextual fear conditioning test was also reduced in
comparison to nTg mice (SI Appendix, Fig. S6N). However, as
the ablation of this protein was also detrimental in nTg mice, the
involvement of Aβ-independent mechanisms cannot be ex-
cluded; however, more studies are necessary to confirm this idea.
Discussion
The activation of brain immune responses through IL-1R1 sig-
naling is critical for host defense. However, excessive or in-
appropriate activation because of unrestrained signaling of this
receptor is detrimental and has been linked to the pathogenesis
of AD (42, 43). Termination of IL-1β–induced inflammatory
response requires the activation of TOM1, which inhibits further
signaling by targeting IL-1R1 to endosomes for efficient lyso-
somal degradation (23, 28). The relevance of intracellular pro-
tein trafficking in the regulation of IL-1β signaling suggests that
dysfunction of endocytosis may result in excessive expression of
IL-1R1, which in turn exacerbates inflammatory responses. We
found that TOM1 deficiency exacerbates the inflammatory
response and increases Aβ plaque deposition. These data suggest
that, even in older animals, restoration of proper receptor in-
ternalization can be beneficial and ameliorate cognitive deficits,
a finding which has strong therapeutic implications.
Our findings are consistent with the notion that up-regulation
of IL-1R1 in the aged hippocampus can potentiate the IL-1β
inflammatory response (18). Previous reports have shown that
the loss of synaptic connections induced by IL-1β requires both
pre- and postsynaptic mechanisms (15), which could explain the
detrimental consequences of the increased receptor expression
observed in our study. IL-1β can boost its own expression
through autocrine actions on microglia and paracrine actions on
neurons (44, 45), and, by feeding back upon itself, low levels of
this cytokine may be enough to drive potent neuroinflammatory
changes in the brain. Also, IL-1R1 knockout mice presented a
dramatic reduction in microglial and astrocytic activation as well
as IL-6 and COX-2 production (45, 46). Adding to this evidence,
overexpression of TOM1 suppressed the activation of the tran-
scription factors nuclear factor-κB and activator protein 1 in re-
sponse to IL-1β or TNF-α (47), and knockdown of TOM1 also
resulted in the accumulation of IL-1R1 at late-stage endosomes (25).
Microglia are responsible for engulfing and degrading differ-
ent types of brain cargo such as apoptotic cells and protein de-
posits (48), and the imbalance between protein production and
degradation contributes to the characteristic extracellular accu-
mulation of Aβ in AD brains. Oligomeric Aβ can activate
microglia cells to induce neuroinflammation through processing
of IL-1β, enhancing microglial neurotoxicity (49). Accordingly,
infusion of human Aβ in mice lacking the IL-1 receptor antag-
onist induced microglial activation and pronounced loss of syn-
aptic markers (50). Here, knocking down TOM1 led to a reduced
microglial branching and processes length and p62 levels,
resulting in increased plaque load as well as Aβ levels. More
importantly, increasing TOM1 levels in microglia significantly
augmented the rate of ADDLs and Aβ fibrils phagocytosis,
suggesting that the TOM1/IL-1R1 complex may play an addi-
tional role in the glial response to amyloid uptake (i.e., phago-
cytosis). A distinct phagocytic response of microglial cells to both
Aβ oligomers and fibrils has been shown, whereas exposure of
microglia to fibrils enhanced phagocytosis (51), which could also
explain the faster rate at which we observed fibril phagocytosis in
Fig. 5. TOM1 overexpression alters BACE1 and p62 levels proteins. Representative Western blots and quantification show increased APP (A) in all 3xTg-AD
groups. BACE was reduced in TOM1-WPRE compared to Null and TOM1-shRNA 3xTg-AD mice (E), but no significant changes were found in APOE (B),
ADAM10 (C), or ADAM17 (D). Moreover, TOM1 overexpression increased the levels of p62 (F) without changing the LC3-II/I ratio (G). Data are represented as
mean ± SEM. ANOVA, *P ≤ 0.05; n = 4 per group.
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our study. Interestingly, increasing TOM1 levels exacerbated the
internalization of ADDLs, an important finding, as Aβ oligomers
are considered the most deleterious form of this peptide.
The specialized process of protein internalization requires the
ubiquitylation of cargo proteins and endocytosis, as well as protein-
sorting complexes, followed by cargo delivery into early endosomes
(52). Once internalized, cargo is further sorted through late endo-
somes and delivered for degradation in lysosomes. The endosomal
signaling depends on the presence of highly specialized adaptor
proteins, such as the TOM1 family (53, 54). TOM1 interacts with
clathrin, implying its role in membrane trafficking (54), and the
TOM1/Tollip association inhibits binding of Tollip to phosphati-
dylinositol 3-phosphate, facilitating its involvement in the TOM1-
mediated endosomal cargo trafficking (27). TOM1 levels are re-
duced in AD brains (35, 55, 56) and, given the important body of
evidence recently indicating that disturbed vesicular trafficking has a
special relevance in AD pathogenesis (29, 31, 57, 58), the modu-
lation of endocytosis and signaling may provide an effective means
of regulating IL-1β–triggered inflammation in AD.
The initial amyloidogenic processing of APP by BACE1 occurs
in the early endosomes (59). Additionally, the enlarged endo-
somes that are present in the early stages of AD (60) could be a
result of abnormal internalization of BACE1 and APP, resulting
in increased Aβ production. The rapid trafficking of BACE1 to
recycling endosomes, coupled with reduced levels of APP and Aβ
production, is mediated by GGA1 (61). GGAs (Golgi-localizing,
γ-adaptin ear domain homology, ARF-binding proteins) are a
family of monomeric adaptor proteins that regulate clathrin-
mediated trafficking to endosomes. The GGA molecule is
composed of four distinct domains, being the TOM1 part of the
GAT domain (62). It has been recently shown that TOM1 at-
tenuated the neuronal accumulation of Aβ through binding to
the Fcγ-receptor IIb (FcγRIIb) in male 3xTg-AD mice (63). In
our study, overexpression of TOM1 resulted in reduced levels of
BACE1 in 3xTg-AD mice, suggesting that the dysregulation of
BACE1 internalization might be a fundamental mechanism in
the increased plaque formation observed.
Importantly, our data underscore an important mechanism
through which IL-1β and IL-1R1 are related to Aβ accumulation.
Our results demonstrate that changes in TOM1-mediated endocy-
tosis are Aβ-triggered events leading to exacerbated inflammatory
response and cognitive decline. Thus, embracing the restoration of
TOM1-controlled inflammatory pathways therapeutically repre-
sents a promising strategy for the restoration of the aged immune
system, which might prove effective for a healthy aging and control
of age-dependent chronic neurodegenerative disorders.
Methods
Transgenic Mice. All experiments were conducted with female homozygous
3xTg-AD and nTg mice aged 12 mo on a hybrid 129/C57BL6 background. The
generation and characterization of the 3xTg-AD mice has been previously
described (16). All animal procedures were performed in accordance with
National Institutes of Health and University of California guidelines and
were approved by the Institutional Animal Care and Use Committee at the
University of California, Irvine.
Human Tissue. The University of California Irvine Alzheimer’s Disease Research
Center provided the samples of human hippocampus from nondemented
and AD subjects (SI Appendix, Table S1). The protocols for obtaining post-
mortem brain tissue complied with all federal and institutional guidelines
with special respect for donor identity confidentiality and informed consent.
Infusion of Vectors. Stereotactic injection of AAV1-Null, AAV1-CAG-mTom1-
WPRE, AAV1-GFP-U6-mTom1-shRNA, and AAV1-GFP-U6-mTollip-shRNA into
the hippocampus was performed according to previously described surgical
protocols (64). Female 9-mo-old 3xTg-AD mice were anesthetized and placed
in stereotaxic apparatus under continuous isoflurane anesthesia. Two mi-
croliters of each AAV (1 × 1010 genome particles/mL, Vector Biolabs) were
injected at the following stereotaxic coordinates—anterior–posterior: −2.06 mm;
dorsoventral: −1.95 mm; and mediolateral: ±1.75 mm. Animals were allowed to
Fig. 6. Overexpression of TOM1 improves cognition. Knocking down TOM1 worsened the cognition of 3xTg-AD mice in the acquisition of the Morris water
maze test (A). TOM1-shRNA also reduced the time spent in the target zone (B) and the number of crosses (C), while increasing the latency to platform (D). No
significant changes were observed in distance (E) or speed (F) (a single asterisk represents significance vs. nTg group and “#” represents significance vs. TOM1-
WPRE groups). TOM1-shRNA also reduced the freezing behavior in the contextual fear-conditioning paradigm (G). No significant changes were observed for
the discrimination index during novel object recognition test (H). Representative Western blots and quantification show no significant changes in BDNF or
pCREB/CREB ration in all 3xTg-AD groups (I–K). Data are represented as mean ± SEM. ANOVA, *P ≤ 0.05; n = 4–10 per group.
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recover on a heating pad before being placed back in their home cages. Be-
havioral experiments and brain collection were performed 3 mo after the in-
fusion of vectors.
Lentiviral Transduction and ADDLS Treatment in iPSC-Derived Human Microglia
Cells. iPSC microglia were differentiated according to previously published
protocols (65). iPSC microglia were preincubated with 6 μg/mL polybrene for
1 h. Lentiviral particles [Lenti ORF particles, TOM1 (Myc-DDK-tagged)-
Human target of myb1 (chicken) (TOM1), transcript variant 1, and Lenti
ORF control particles of pLenti-C-Myc-DDK-P2A-Puro, OriGene] were resus-
pended in fresh medium supplemented with 6 μg/mL polybrene at 1.25 × 106
transduction units per milliliter. Viral particles were added to Matrigel-
coated plates and covered with 1 million iPSC microglia (MOI 1.25). Fresh
medium was added for the next 2 d, and cells were harvested 3 d post
transduction. Mature iPSC microglia were treated with 100 or 500 nM ADDL
or vehicle for 24 or 48 h. ADDLs and fluorescent-tagged ADDLs (Anaspec
HiLyte555) were prepared as previously described protocols (66). ADDL
concentration was determined by Nanodrop (ThermoFisher Scientific) and
fluorescent-tagged ADDL concentration was determined by interpolating to
a standard curve of a 555-tagged protein (goat anti-mouse Alexa 555). For
fibrils, fluorescent Aβ was resuspended in 0.1% NH4OH, diluted to 100 μg/mL
in sterile RNase/DNase free H2O, and allowed to fibrillize for 1 wk at 37 C
before use. At collection, iPSC microglia were washed with ice-cold Dulbecco’s
phosphate-buffered saline and lysed in SDS buffer (1% SDS, 1 mM Na3VO4,
10 mM Tris·HCl [pH 7.4]) with 20× trituration.
Real-Time Phagocytosis Assay.Mature iPSC microglia were plated on Matrigel
(Corning) at 40% confluence and allowed to settle for 20 min. Next, Aβ
preparations were added at the indicated concentrations and imaged hourly
on the Essen S3 IncuCyte (Essen Biosciences) live-cell imaging platform. After
image acquisition, masks of phase and fluorescent signal were generated
with IncuCyte analysis software. Fluorescent signal was normalized to phase
confluence to generate percentage of phagocytosis.
Behavior Paradigms. Behavioral analyses were done 3 mo after the infusion
of vectors.
Novel object. Each mouse was habituated to an empty Plexiglas arena (45 ×
25 × 20 cm) for 4 consecutive days prior to testing. The lighting intensity in
each behavioral task was measured at 44 l×. Mice were exposed to 2 iden-
tical objects placed at opposite ends of the arena for 10 min. After 24 h, mice
were presented for 10 min with one of the familiar and a novel object of
similar dimensions. The discrimination index represents the percentage of
time that mice spent exploring the novel object (67).
Morris water maze. Mice were trained to swim to a 14-cm diameter circular
clear Plexiglas platform submerged 1.5 cm beneath the surface. Four trials
were performed per day, for 60 s each with a 5-min interval between trials.
The probe test was assessed 24 h after the last trial, with the platform re-
moved. Performance was monitored with the EthoVision XT video-tracking
system (Noldus Information Technology).
Contextual fear conditioning. During training, mice were placed in the fear-
conditioning chamber and allowed to explore for 2 min before receiving 3
electric foot shocks (duration: 1 s; intensity: 0.2 mA; intershock interval: 2 min).
Twenty-four hours later, behavior in the conditioning chamber was observed
and analyzed for freezing behavior during 5 min.
Imaris Quantitative Analysis. Volumetric image measurements were made in
the hippocampus using Imaris software (Bitplane Inc.). Amyloid burden was
acquired by measuring the total number of Aβ plaques and their size,
expressed in area units (μm2) in the whole hippocampal area analyzed. The
6E10-immunopositive signal (Aβ plaques) within the selected brain region
was identified by a threshold level mask, which was maintained throughout
the whole analysis for uniformity. The total number of amyloid plaques and their
area was obtained automatically by Imaris software. Quantitative comparisons
between groups were always carried out on comparable sections of each animal
processed at the same time with the same batches of solutions. Microglial and
astroglial loading were defined as the percentage of area stained with anti–Iba1/
anti-GFAP related to the hippocampal area analyzed (CA1 + subiculum). The Iba1/
GFAP-immunopositive signal within the selected brain region was again identified
by a threshold level mask (maintained throughout the whole analysis). All pa-
rameters analyzed were obtained with the Bitplane Imaris software.
Electron Microscopy Immunogold Labeling. Electron microscopy labeling of IL-
1R1 was performed as previously described (68). Coronal sections were first
cryoprotected in a 25% sucrose and 10% glycerol solution, followed by
freezing at −80 °C in order to increase the antibody binding efficiency. The
tissue was then incubated with IL1-R1 primary antibody for 48 h at 22 °C
followed by the incubation with 1.4 nm of gold-conjugated secondary an-
tibody (1:100, Nanoprobes) overnight at 22 °C. After postfixing with 2% glu-
taraldehyde, the labeling was enhanced with the HQ SilverTM Kit
(Nanoprobes), and gold-toned. Immunolabeled sections were fixed in osmium
tetroxide, block-stained with uranyl acetate, dehydrated in graded acetone,
and embedded in Araldite (EMS). Selected areas were cut in ultrathin sections
(70 nm) and examined with an electron microscope (JEOL JEM 1400).
Statistical Analysis. All data were analyzed by Student’s t test comparisons,
between 2 groups, and 1- or 2-way ANOVA, followed by Tukey’s test for
comparisons among more than 2 groups using Prism version 6.0 (GraphPad
Software). P < 0.05 was considered significant, and the significance was set at
95% of confidence. Western blots, immunostainings, and cell culture analyses
were repeated 3 to 4 times with similar results. Electrochemiluminescence-
linked immunoassays were performed in duplicates. All values are presented
as mean ± SEM.
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